Novel hydrophilic docetaxel (CQMU-0519) analogue inhibits proliferation and induces apoptosis in human A549 lung, SKVO3 ovarian and MCF7 breast carcinoma cell lines

Cell Proliferation

Volumn 45, Issue 4, 2012, Pages 352-364

  Fauzee, N J S ^a   Wang, Y L ^a   Dong, Z ^a   Li, Q G ^a   Wang, T ^a   Mandarry, M T ^b   Xu, L ^a   Pan, J ^a  

^a CHONGQING MEDICAL UNIVERSITY   (China)

^b THE FIRST AFFILIATED HOSPITAL OF CHONGQING MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CASPASE 3; CASPASE 6; CASPASE 8; CASPASE 9; CQMU0519; DOCETAXEL; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PROTEIN BAD; PROTEIN BAX; PROTEIN BCL 2; PROTEIN BCL XL; TAXANE DERIVATIVE; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; BREAST CARCINOMA; CANCER GROWTH; CELL CYCLE G0 PHASE; CELL CYCLE G1 PHASE; CELL POPULATION; CELL PROLIFERATION; CELL VIABILITY; COMPARATIVE STUDY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DNA FRAGMENTATION; DOWN REGULATION; DRUG SOLUBILITY; ENZYME ACTIVATION; FLOW CYTOMETRY; G2 PHASE CELL CYCLE CHECKPOINT; HUMAN; HUMAN CELL; HYDROPHILICITY; LUNG CARCINOMA; OVARY CARCINOMA; PROTEIN CLEAVAGE; PROTEIN EXPRESSION; WESTERN BLOTTING;

ANTINEOPLASTIC AGENTS; APOPTOSIS; BLOTTING, WESTERN; BREAST NEOPLASMS; CASPASES; CELL LINE, TUMOR; COLORIMETRY; ENZYME ACTIVATION; FEMALE; HUMANS; LUNG NEOPLASMS; OVARIAN NEOPLASMS; POLY(ADP-RIBOSE) POLYMERASES; PROTO-ONCOGENE PROTEINS C-BCL-2; TAXOIDS;

EID: 84862882487     PISSN: 09607722     EISSN: 13652184     Source Type: Journal    
DOI: 10.1111/j.1365-2184.2012.00825.x     Document Type: Article

References (52)

1. Bissery MC, Guénard D, Guéritte-Voegelein F, Lavelle F (1991) Experimental antitumor activity of taxotere (RP56976, NSC 628503), a taxol analogue. Cancer Res. 51, 4845-4852.
2. Hennenfent KL, Govindan R (2006) Novel formulations of taxanes: a review. Old wine in a new bottle? Ann. Oncol. 17, 735-749.
3. Calderoni A, Cerny T (2001) Taxanes in lung cancer: a review with focus on the European experience. Crit. Rev. Oncol. Hematol. 38, 105-127.
4. Rao S, He L, Chakravarty S, Ojima I, Orr GA, Horwitz SB (1999) Characterization of the Taxol binding site on the microtubule. Identification of Arg282 in β-tubulin as the site of photoincorporation of a 7-benzophenone analogue of taxol. J. Biol. Chem. 274, 37990-37994.
5. Snyder JP, Nettles JH, Cornett B, Downing KH, Nogales E (2001) The binding conformation of Taxol in b-tubulin: a model based on electron crystallographic density. Proc. Natl. Acad. Sci. USA 98, 5312-5316.
6. Yvon AMC, Wadsworth P, Jordan MA (1999) Taxol suppresses dynamics of individual microtubules in living human tumor cells. Mol. Biol. Cell 10, 947-959.
7. Jordan MA, Wilson L (1998) Microtubules and actin filaments: dynamic targets for cancer chemotherapy. Curr. Opin. Cell Biol. 10, 123-130.
8. Derry WB, Wilson L, Jordan MA (1995) Substoichiometric binding of taxol suppresses microtubule dynamics. Biochemistry 34, 2203-2211.
9. Schiff PB, Fant J, Horwitz SB (1979) Promotion of microtubule assembly in vitro by taxol. Nature 277, 665-667.
10. Schiff PB, Horwitz SB (1980) Taxol stabilizes microtubules in mouse fibroblast cells. Proc. Natl. Acad. Sci. USA 77, 1561-1565.
11. Jordan MA, Toso RJ, Thrower D, Wilson L (1993) Mechanism of mitotic block and inhibition of cell proliferation by taxol at low concentrations. Proc. Natl. Acad. Sci. USA 90, 9552-9556.
12. Jordan MA, Wendell K, Gardiner S, Derry WB, Copp H, Wilson L (1996) Mitotic block induced in HeLa cells by low concentrations of paclitaxel (Taxol) results in abnormal mitotic exit and apoptotic cell death. Cancer Res. 56, 816-825.
13. Geng CX, Zeng ZC, Wang JY (2003) Docetaxel inhibits SMMC-7721 human hepatocellular carcinoma cells growth and induces apoptosis. World J. Gastroenterol. 9, 696-700.
14. Mhaidat NM, Zhang XD, ChenJiang C, Hersey P (2007) Docetaxel-induced apoptosis of human melanoma is mediated by activation of c-Jun NH2-terminal kinase and inhibited by the mitogen-activated protein kinase extracellular signal-regulated kinase 1/2 pathway. Clin. Cancer Res. 13, 1308-1314.
15. Kang J, Wu X, Wang Z, Ran H, Xu C, Wu J et al. (2010) Antitumor effect of docetaxel-loaded lipid microbubbles combined with ultrasound-targeted microbubble activation on VX2 rabbit liver tumors. J. Ultrasound Med. 29, 61-70.
16. Ichite N, Chougule MB, Jackson T, Fulzele SV, Safe S, Singh M (2009) Enhancement of docetaxel anticancer activity by a novel diindolylmethane compound in human non-small cell lung cancer. Clin. Cancer Res. 15, 543-552.
17. Mahaffey CM, Davies AM, Lara PN Jr, Pryde B, Holland W, Mack PC et al. (2007) Schedule dependent apoptosis in K-ras mutant non-small-cell lung cancer cell lines treated with docetaxel and erlotinib: rationale for pharmacodynamic separation. Clin. Lung Cancer 8, 548-553.
18. Nehmé A, Varadarajan P, Sellakumar G, Gerhold M, Niedner H, Zhang Q et al. (2001) Modulation of docetaxel-induced apoptosis and cell cycle arrest by all-trans retinoic acid in prostate cancer cells. Br. J. Cancer 84, 1571-1576.
19. Wang QW, Lu HL, Song CC, Liu H, Xu CG (2005) Radiosensitivity of human colon cancer cell enhanced by immunoliposomal docetaxel. World J. Gastroenterol. 11, 4003-4007.
20. Ferlini C, Di Stefano M, Marone M, Gaggini C, Ferrandina G, Riva A et al. (1998) The synergistic anti-tumour activity of ICI 182, 780 in combination with docetaxel is mediated by P-glycoprotein inhibition. Endocr. Relat. Cancer 5, 315-324.
21. Choe MS, Chen Z, Klass CM, Zhang X, Shin DM (2007) Enhancement of docetaxel-induced cytotoxicity by blocking epidermal growth factor receptor and cyclooxygenase-2 pathways in squamous cell carcinoma of the head and neck. Clin. Cancer Res. 13, 3015-3023.
22. Wang Z, Goulet R III, Stanton KJ (2005) Differential effect of anti-apoptotic genes Bcl-xL and c-FLIP on sensitivity of MCF-7 breast cancer cells to paclitaxel and docetaxel. Anticancer Res. 25, 2367-2380.
23. Hwang JJ, Kim YS, Kim MJ (2010) Histone deacetylase inhibitor potentiates anticancer effect of docetaxel via modulation of Bcl-2 family proteins and tubulin in hormone refractory prostate cancer cells. J. Urol. 184, 2557-2564.
24. Chang JT, Chang GC, Ko JL, Liao HY, Liu HJ, Chen CC et al. (2006) Induction of tubulin by docetaxel is associated with p53 status in human non small cell lung cancer cell lines. Int. J. Cancer 118, 317-325.
25. Mediavilla-Varela M, Pacheco FJ, Almaguel F, Perez J, Sahakian E, Daniels TR et al. (2009) Docetaxel-induced prostate cancer cell death involves concomitant activation of caspase and lysosomal pathways and is attenuated by LEDGF/p75. Mol. Cancer. doi: 10.1186/1476-4598-8-68.
26. Mhaidat NM, Wang Y, Kiejda KA, Zhang XD, Hersey P (2007) Docetaxel induced apoptosis in melanoma cells is dependent on activation of caspase-2. Mol. Cancer Ther. 6, 752-761.
27. Katopodis O, Polyzos A, Kentepozidis N, Giassas S, Rovithi M, Bozionelou V et al. (2010) Second line chemotherapy with capecitabine (Xeloda) and docetaxel (Taxotere) in previously treated, unresectable adenocarcinoma of pancreas: the final results of a phase II trial. Cancer Chemother. Pharmacol. doi: 10.1007/s00280-010-1329-6.
28. Mäenpaä JU (2003) Docetaxel: promising and novel combinations in ovarian cancer. Br. J. Cancer 89, S29-S34.
29. Wenzel C, Steger GG (2006) Adjuvant treatment of breast cancer with Taxanes. Breast Care 1, 171-175.
30. Pectasides D, Pectasides M, Farmakis D, Kostopoulou V, Nikolaou M, Gaglia A et al. (2005) Comparison of docetaxel and docetaxel-irinotecan combination as second-line chemotherapy in advanced non-small-cell lung cancer: a randomized phase II trial. Ann. Oncol. 16, 294-299.
31. Nabell L, Spencer S (2003) Docetaxel with concurrent radiotherapy in head and neck cancer. Semin. Oncol. 30, 89-93.
32. Huang TSW, Northrup S (2004) The cytotoxicity of combined paricalcitol and docetaxel in head and neck squamous cell carcinomas. J. Clin. Oncol. (Meeting Abstracts) 22, 14S-5609.
33. O'Neill AJ, Prencipe M, Dowling C, Fan Y, Mulrane L, Gallagher WM et al. (2011) Characterisation and manipulation of docetaxel resistant prostate cancer cell lines. Mol. Cancer. 10, 126. doi: 10.1186/1476-4598-10-126.
34. Clarke SJ, Rivory LP (1999) Clinical pharmacokinetics of docetaxel. Clin. Pharmacokinet. 36, 99-114.
35. Gridelli C, Rossi A, Venturino P, De Marinis F (2011) Treatment, Rationale, and Study Design of TALISMAN Study: a randomized phase II open-label study of second-line erlotinib versus intermittent erlotinib dosing with docetaxel in the treatment of former-smoker men affected by recurrent squamous non-small-cell lung cancer. Clin. Lung Cancer 12, 70-73.
36. Langlois NEI, Eremin O, Heys SD (2000) Apoptosis and prognosis in cancer: rationale and relevance. J. R. Coll. Surg. Edinb. 45, 211-219.
37. Biscotti CV, Hart WR (1998) Apoptotic bodies: a consistent morphologic feature of endocervical adenocarcinoma in situ. Am. J. Surg. Pathol. 22, 434-439.
38. Grant DS, Williams TL, Zahaczewsky M, Dicker AP (2003) Comparison of antiangiogenic activities using Paclitaxel (TAXOL) and Docetaxel (TAXOTERE). Int. J. Cancer 104, 121-129.
39. Fabbri F, Carloni S, Brigliadori G, Zoli W, Lapalombella R, Marini M (2006) Sequential events of apoptosis involving docetaxel, a microtubule-interfering agent: a cytometric study. BMC Cell Biol. doi: 10.1186/1471-2121/7/6.
40. Matsushima T, Nakashima M, Oshima K, Abe Y, Nishimura J, Nawata H et al. (2001) Receptor binding cancer antigen expressed on SiSo cells, a novel regulator of apoptosis of erythroid progenitor cells. Blood 98, 313-321.
41. Ofir R, Sedman R, Rabinski T, Krup M, Yavelsky V, Weinstein Y et al. (2002) Taxol-induced apoptosis in human SKOV3 ovarian and MCF7 breast carcinoma cells is caspase-3 and caspase-9 independent. Cell Death Differ. 9, 636-642.
42. Blanc C, Deveraux QL, Krajewski S, Jänicke RU, Porter AG, Reed JC et al. (2000) Caspase 3 is essential for procaspase 9 processing and cisplatin induced apoptosis of MCF-7 breast cancer cells. Cancer Res. 60, 4386-4390.
43. Kagawa S, Gu J, Honda T, McDonnell TJ, Swisher SG, Roth JA et al. (2001) Deficiency of caspase-3 in MCF7 cells blocks bax-mediated nuclear fragmentation but not cell death. Clin. Cancer Res. 7, 1474-1480.
44. Muhamad S, Pihie AHL, Latif J, Rha C-K, Sambandan TG (2011) Induction of apoptosis in MCF-7 via the caspase pathway by longilactone from Eurycoma longifolia Jack. Res. Pharm. Biotechnol. 3, 1-10.
45. Mooney LM, Al-Sakkaf KA, Brown BL, Dobson PR (2002) Apoptotic mechanisms in T47D and MCF-7 human breast cancer cells. Br. J. Cancer 87, 909-917.
46. Gooch JL, Yee D (1999) Strain specific differences in formation of apoptotic DNA ladders in MCF-7 breast cancer cells. Cancer Lett. 144, 31-37.
47. Özlem DI, Meltem DK, Ufuk G (2011) Two different docetaxel resistant MCF-7 sublines exhibited different gene expression pattern. Mol. Biol. Rep. doi: 10.1007/s11033-011-1123-5.
48. Fauzee NJS, Pan J, Wang YL (2010) PARP and PARG inhibitors-new therapeutic targets in cancer treatment. Pathol. Oncol. Res. 16, 469-478.
49. Perry DK, Smyth MJ, Wang HG (2002) Bcl2 acts upstream of the PARP protease and prevents its activation. Cell Death Differ. 4, 29-33.
50. Fukazawa T, Maeda Y, Matsuoka J, Tanaka N, Tanaka H, Durbin ML et al. (2009) Drug-regulatable cancer cell death induced by BID under control of the tissue-specific, lung cancer-targeted TTS promoter system. Int. J. Cancer 125, 1975-1984.
51. Li H, Zhu H, Xu CJ, Yuan J (1998) Cleavage of BID by caspase 8 mediates the mitochondrial damage in the Fas pathway of apoptosis. Cell 94, 491-501.
52. Fauzee NJS, Dong Z, Wang YL (2011) Taxanes: promising anti-cancer drugs. Asian Pasific J. Cancer Prev. 12, 837-851.